Literature DB >> 11357147

Haematopoietic cell transplantation as immunotherapy.

F R Appelbaum1.   

Abstract

The graft-versus-tumour effect seen after allogeneic (genetically different) haematopoietic cell transplantation for human malignancies represents the clearest example of the power of the human immune system to eradicate cancer. Recent advances in our understanding of the immunobiology of stem-cell engraftment, tolerance and tumour eradication are allowing clinicians to better harness this powerful effect.

Entities:  

Mesh：

Year:  2001        PMID： 11357147     DOI： 10.1038/35077251

Source DB:  PubMed          Journal:  Nature        ISSN： 0028-0836            Impact factor:   49.962


  140 in total

1.  Reduced graft-versus-host disease in C3-deficient mice is associated with decreased donor Th1/Th17 differentiation.

Authors:  Qing Ma; Dan Li; Roza Nurieva; Rebecca Patenia; Roland Bassett; Wei Cao; Andrei M Alekseev; Hong He; Jeffrey J Molldrem; Michael H Kroll; Richard E Champlin; George E Sale; Vahid Afshar-Kharghan
Journal:  Biol Blood Marrow Transplant       Date:  2012-06-01       Impact factor: 5.742

Review 2.  Suicide-gene-Transduced donor T-cells for controlled graft-versus-host disease and graft-versus-tumor.

Authors:  Fabio Ciceri; Claudio Bordignon
Journal:  Int J Hematol       Date:  2002-11       Impact factor: 2.490

3.  Bone marrow transplants.

Authors:  Peter W M Johnson; Kim Orchard
Journal:  BMJ       Date:  2002-08-17

4.  Adoptive transfer of PR1 cytotoxic T lymphocytes associated with reduced leukemia burden in a mouse acute myeloid leukemia xenograft model.

Authors:  Qing Ma; Changqing Wang; Dan Jones; Kathryn E Quintanilla; Dan Li; Yang Wang; Eric D Wieder; Karen Clise-Dwyer; Gheath Alatrash; You Mj; Mark F Munsell; Sijie Lu; Muzaffar H Qazilbash; Jeffrey J Molldrem
Journal:  Cytotherapy       Date:  2010-08-24       Impact factor: 5.414

5.  L-selectin is dispensable for T regulatory cell function postallogeneic bone marrow transplantation.

Authors:  M J Carlson; L M Fulton; J M Coghill; M L West; J E Burgents; Y Wan; A Panoskaltsis-Mortari; T F Tedder; B R Blazar; J S Serody
Journal:  Am J Transplant       Date:  2010-11-10       Impact factor: 8.086

6.  Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells.

Authors:  Chihaya Imai; Shotaro Iwamoto; Dario Campana
Journal:  Blood       Date:  2005-03-08       Impact factor: 22.113

Review 7.  Genetically engineered donor T cells to optimize graft-versus-tumor effects across MHC barriers.

Authors:  Arnab Ghosh; Amanda M Holland; Marcel R M van den Brink
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

8.  Secondary anchor polymorphism in the HA-1 minor histocompatibility antigen critically affects MHC stability and TCR recognition.

Authors:  Sarah Nicholls; Karen P Piper; Fiyaz Mohammed; Timothy R Dafforn; Stefan Tenzer; Mahboob Salim; Premini Mahendra; Charles Craddock; Peter van Endert; Hansjörg Schild; Mark Cobbold; Victor H Engelhard; Paul A H Moss; Benjamin E Willcox
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-20       Impact factor: 11.205

9.  The MEK inhibitor trametinib separates murine graft-versus-host disease from graft-versus-tumor effects.

Authors:  Hidekazu Itamura; Takero Shindo; Isao Tawara; Yasushi Kubota; Ryusho Kariya; Seiji Okada; Krishna V Komanduri; Shinya Kimura
Journal:  JCI Insight       Date:  2016-07-07

10.  In vitro-differentiated TH17 cells mediate lethal acute graft-versus-host disease with severe cutaneous and pulmonary pathologic manifestations.

Authors:  Michael J Carlson; Michelle L West; James M Coghill; Angela Panoskaltsis-Mortari; Bruce R Blazar; Jonathan S Serody
Journal:  Blood       Date:  2008-10-28       Impact factor: 22.113
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.